Apixaban and Alteplase, Recombinant: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Alteplase, Recombinant
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Apixaban (Eliquis) is a blood thinner that keeps clots from forming. Alteplase (Activase) is a clot-buster, a powerful medicine given in the hospital to break up a dangerous clot, such as during a stroke or heart attack. Both make it harder for your blood to clot, so using them together adds up and can raise your risk of serious bleeding.
This combination usually only happens in an emergency setting where your care team is watching you very closely. The good news is this is very manageable. Your team will check for any signs of bleeding, run blood tests, and keep a close eye on you so they can act quickly if needed.
Effect: Additive bleeding risk when apixaban (direct factor Xa inhibitor) is combined with alteplase (fibrinolytic). Neither agent is a prodrug; both independently impair hemostasis, so the risk is pharmacodynamic and additive rather than PK-mediated.
Severity: Major. Onset: unspecified. Evidence: theoretical.
Management:
- Monitor clinically for external and internal bleeding.
- Laboratory monitoring including appropriate anticoagulation tests and PT.
- Observe surgical wound drainage; measure Hb periodically.
- Suspect bleeding if Hb falls or blood pressure drops.
Note: low-intensity warfarin (INR
What happens
An increased risk of bleeding
Interaction Deep Dive
When an anticoagulant is taken together with a fibrinolytic (for example, a thrombolytic) agent, additive effects may raise the likelihood of major bleeding1. Safe joint administration has been shown in two studies, one involving low-dose warfarin4 and another involving low-intensity warfarin therapy (that is, an INR of 1.7 or less) alongside a thrombolytic agent5. Nonetheless, when combined use of an anticoagulant and a fibrinolytic agent cannot be avoided, patients should undergo clinical monitoring for indications and symptoms of bleeding, whether external or internal. Monitoring through laboratory tests is likewise recommended2. Drainage from surgical wounds should be watched closely. A drop in Hb levels or a fall in blood pressure should prompt suspicion of bleeding3.
Why it happens (mechanism)
Additive effects
How to manage this interaction
This combination is typically used only in a monitored, often emergency, setting. Keep taking your medications exactly as prescribed and do not stop either one on your own.
Your care team will manage this by:
- Watching closely for external bleeding and signs of internal bleeding.
- Running blood tests, including clotting tests and hemoglobin checks.
- Monitoring surgical wounds and your blood pressure.
Tell your team right away if you notice unusual bruising, bleeding that won't stop, pink or dark urine, black stools, severe headache, dizziness, or weakness. These may signal bleeding that needs prompt attention.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) In clinical studies of patients undergoing percutaneous transluminal coronary angioplasty (PTCA) or percutaneous coronary intervention (PCI), giving bivalirudin together with thrombolytic agents, glycoprotein IIb/IIIa inhibitors, warfarin, or heparin was linked to a greater risk of major bleeding events compared with patients who did not receive these concurrent medications 1. Any drug capable of raising the risk of hemorrhage should be stopped before starting desirudin therapy 2.
b) A Finnish study assessing the combined use of streptokinase and oral anticoagulants for treating DVT reported that, even though reduced doses were used during the streptokinase infusion, warfarin administration caused no problems. Forty-four patients were initially given warfarin 0.5 mg along with streptokinase 600,000 international units. Streptokinase 600,000 international units/hour was maintained for 3 days, and phlebography was performed to assess resolution of the thrombotic occlusion. If lysis remained incomplete, treatment continued for another 3 days. When required, warfarin was administered to maintain the protein phosphatase (PP) activity level at 0.1 to 0.2. Bleeding led to the discontinuation of treatment in 8 of the 44 patients (18.2%). Although this study records the concurrent use of oral anticoagulants and streptokinase, both the anticoagulant and streptokinase were begun at the same time. Because 3 to 5 days are needed before hypoprothrombinemia develops, these patients did not undergo the true interaction whereby the thrombolytic effect of streptokinase combines with hypoprothrombinemia caused by the concurrent use of warfarin 4.
c) In a study examining registry data from 45,074 patients who received IV tissue plasminogen activator for acute ischemic stroke, there was no significant rise in the risk of symptomatic intracerebral hemorrhage or death among patients on warfarin therapy with an INR of 1.7 or less (n=768) compared with patients not receiving warfarin (n=43,651), after adjusting for age, stroke severity, and comorbidities 5.
Common questions
Can I take Apixaban and Alteplase, Recombinant together?
Combining apixaban with alteplase adds up their blood-thinning effects and raises bleeding risk, so this is done only under close monitoring. Report any signs of bleeding to your care team immediately. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Apixaban and Alteplase, Recombinant interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Apixaban and Alteplase, Recombinant interaction managed?
This combination is typically used only in a monitored, often emergency, setting. Keep taking your medications exactly as prescribed and do not stop either one on your own. Your care team will manage this by: Watching closely for external bleeding and signs of internal bleeding. Running blood tests, including clotting tests and hemoglobin checks. Monitoring surgical wounds and your blood pressure.… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Apixaban or Alteplase, Recombinant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Product Information: ANGIOMAX(R) IV injection, bivalirudin IV injection. The Medicines Company, Parsippany, NJ, 2005.
- Product Information: Iprivask(TM), desirudin for injection. Aventis Pharmaceuticals Inc. Bridgewater, NJ, 2003.
- Product Information: Xarelto(R) oral film-coated tablets, rivaroxaban oral film-coated tablets. Bayer HealthCare (per manufacturer), Leverkusen, Germany, 2008. DailyMed
- Jarvinen P, Aromaa U, Roiha M, et al: Streptokinase and concomitant oral anticoagulants in the treatment of deep venous thrombosis. Klin Wochenschr 1978; 56:801-804. PubMed
- Mazya MV, Lees KR, Markus R, et al: Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013; 74(2):266-274. DOI
Keep reading about Apixaban
Keep reading about Alteplase, Recombinant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist